The Clinical Benefits of Antiresorptive Agents in Primary Breast Cancer Patients Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis.

Sheng-Fan WangYi-Sheng LinWan-Yu YehYuh-Lih ChangChern-En ChiangChen-Huan ChenLing-Ming TsengHsin-Chen LeeChun-Yu Liu Babangida S Chori

Published in: The Journal of clinical endocrinology and metabolism (2023)

Using antiresorptive agents early in breast cancer patients receiving adjuvant endocrine therapy may provide additional benefits in risk reduction of recurrence, but has its potential risk of ONJ.

Keyphrases

early stage
stem cells
mesenchymal stem cells
young adults